Myc is implicated in the control of growth in a variety of cell types. I investigated c-myc gene expression in several lymphoid cell lines to determine the response to cyclic AMP. Cyclic AMP causes a precipitous decline in c-myc message concentration that precedes G1 cell cycle arrest in wild type S49 cells but not in KIN-cells that lack cAMP dependent PKA activity. In wild-type S49 cells washout of cyclic AMP restores c-myc message levels within 2 h but does not relieve the G1 arrest until 10 h later. Transcription runoff studies demonstrate inhibition of both transcriptional initiation and prolongation of initiated transcripts. However, the degree of inhibition is insufficient to explain the absence of detectable myc message suggesting that the predominant effect of cyclic AMP is to destabilize the c-myc message. In contrast to wild-type cells, the "Deathless" mutant S49 cell line is viable when arrested in G1 by exposure to cyclic AMP and has preserved c-myc expression. Thus, in S49 cells down regulation of c-myc expression appears to be associated with loss of viability rather than G1 cell cycle arrest. Interestingly, CEM human T lymphoma cells do not arrest in G1 phase when exposed to cyclic AMP in spite of losing detectable c-myc gene expression. This suggests that in some T lymphoma cells c-myc gene expression may not be necessary for cell cycle progression and proliferation. (J. Clin. Invest.
Introduction
The c-myc proto-oncogene encodes a 64-kD protein that, when heterodimerized with a related protein MAX, is transcriptionally active, binding to the consensus sequence CACGTG (1, 2) . This transcriptional activity is thought to relate to the putative role of c-myc in cell cycle progression and cell proliferation (3) . Myc gene expression is under complex regulation (reviewed in reference 4) with initiation at three different promoter initiation sites (P0, P1, P2) multiple promoter elements that may regulate transcription (5, 6, 7) transcriptional attenuation after the first exon and rapid message turnover (8, 9) . More recently c-myc has been implicated in an opposite role-that of programmed causing GI cell cycle arrest and cytotoxicity (14) . Both of the properties require protein kinase A activity. Most recently, the inhibitory activity of cyclic AMP has been linked the glucocorticoid response (15) . One of the effects of cyclic AMP in some cell types is to attenuate c-myc expression.
The purpose of this study is to characterize c-myc gene expression in response to cyclic AMP in several T lymphoid cell lines. The specific hypothesis I investigated is whether the cyclic AMP inhibition of cell cycle progression and cytotoxicity correlates with diminished c-myc gene expression.
Methods
Cell culture. S49 mouse T lymphoma cells were grown in DME in the presence of 10% heat-inactivated horse serum in a humidified atmosphere containing 10% CO2 at 370C. CEM human T lymphoma cells were grown in RPMI media in the presence of 10% heat-inactivated fetal bovine serum in a humidified atmosphere containing 5% CO2 at 370C. Experimental cultures were used during logarithmic growth at a density of 0.5-2.0 X 106 cells/ml.
RNA extraction. Total cellular RNA was extracted from cells using guanidine precipitation as previously described ( 16) .
Northern blot analysis. RNA (20 j.g/lane) was fractionated onto a 1% agarose/6% formaldehyde gel by electrophoresis then transferred to a Hybond-N+ (Amersham, Arlington Heights, IL) nylon membrane by capillary action and fixed by incubation at 80C for 2 h. Northern blots were prehybridized for 4-6 h at 42'C in a solution containing 50% formamide, 5X Denhardt's, 5x SSC, 0.5% SDS, and 500 ag/ml denatured salmon sperm DNA. Hybridization was performed by the addition of 1.0 to 2.0 x 106 cpm/ml of 32P-labeled DNA Centrifugal elutriation. Cell cycle-specific populations were obtained by centrifugal elutriation as previously described (16 mg/ml propidium iodide in 0.1% sodium citrate and 0.1% Triton X-100) for 15 Inih. Flow cytometry was carried out (Becton-Dickinson, Rutherford, NJ) on an EPICS V analyzer (Coulter) equipped with a multiparameter data acquisition system (Coulter).
Nuclear runoff transcription assay. The nuclear runoff analysis was carried out as previously described (16) . Nuclei were isolated on a sucrose cushion using the method described by Marzluff (17) . DNA (2 jig) for each of the probes was spotted on Hybond-N+ filters (Amersham) using a slot blot apparatus (Schleicher and Schuell, Keene, NH), except for 18 S, where only 200 ng was used. Densitometry was performed to quantitate the results.
RNase protection analysis. Total cellular RNA was analyzed by the RNase protection assay as described by Zinn (18) . Samples (10 jig of total RNA plus RNA probe) were denatured at 850 for 10 min, followed by hybridization at 560C for 12-14 h. RNase treatment with 10 pg/ml RNase A and 500 u/ml Ti (Sigma Chemical Co.) for 1 h at 330C was followed by addition of 10 jtg/ml proteinase K for 10 min at 370C. The effect of cyclic AMP on transcription of c-myc. Transcriptional regulation of c-myc was analyzed by transcription run off assays using labelled nuclei from treated and untreated S49 cells and immobilized probes for both exon 1 and 2 of the c-myc gene in the sense and antisense orientation (Fig. 4) . At (Fig. 6 C) . Cyclic AMP has similar effects on c-myc message in S49 versus CEM cells again demonstrating a half-life of 20 to 40 min. (Fig. 6 A) . Pretreatment with cycloheximide (3 h) increases the half-life suggesting protein synthesis is necessary to transduce part of the cyclic AMP effect (Fig. 6 B) . A very interesting phenomena occurs when dibutyryl cyclic AMP is added to actinomycin D treated cells. In S49 cells the combination of actinomycin D and cyclic AMP has little effect or perhaps shortens the halflife of c-myc messenger RNA whereas in CEM cells it vastly prolongs the c-myc message half life (Fig. 6 D) . When the half-life of c-myc messenger RNA is determined by the RNase protection assay the rate of diminution is somewhat slower in CEM cells than S49 cells (Fig. 3, graph was investigated by analyzing the mechanism of cyclic AMP inhibition of c-myc gene expression in a variety of different T lymphoma cell lines. The expression of c-myc is an attractive target for cyclic AMP cell cycle arrest since it is closely linked to lymphoid cell proliferation. For example, c-myc dysregulation is associated with transformation of lymphoid malignancies and c-myc is expressed early in the mitogenic response of lymphocytes. Suppression of c-myc expression by antisense oligo nucleotides can inhibit entry into S phase (24) . More recently, it has become clear that uncontrolled c-myc expression, while hastening the cell cycle through GI phase shortening, (25) leads to apoptosis. The mechanism of c-myc induced apoptosis is unknown but can be prevented by the bcl-2 gene that encodes a mitochondrial protein. The physiologic down-regulation of c-myc involves the FOS protein which binds to a negative regulatory sequence in the c-myc promoter (26, 27) .
I confirmed the observations of others that the c-myc gene is expressed at relative stable levels through the cell cycle (28 is strengthened by the uniform correlation of persistent c-myc gene expression with cyclic AMP resistance in S49 T lymphoma mutant cell lines with deficient PKA activity. Given the similarity of c-myc messenger RNA concentrations when cells are exposed to cyclic AMP or actinomycin D, I was surprised by the results of the transcription run-off studies. Based on previous studies by numerous investigators I expected that the mechanism of cyclic AMP inhibition of c-myc gene expression would be attenuation (29) (30) (31) (32) (33) which usually occurs at the end of the first exon (34) (that is unexpressed) although has been reported to occur between the P1 and P2 promoter (35, 36) .
The transcription run-off studies however show no significant attenuation for several hours, which is well beyond the time period when c-myc message concentrations become undetectable. By 1 h there appears to be a 30% decline in transcriptional initiation and an additional 10% decrease in transcript elongation. At this point the message concentration is virtually undetectable suggesting that cyclic AMP affects c-myc message stability in S49 cells. Since c-myc mRNA stability may be altered by protein binding, PKA dependent phosphorylation could influence this effect. A similar effect has been noted in glucocorticoid treated T lymphoma cells (37) .
The prolongation c-myc message with cycloheximide pretreatment is expected since a number of rapidly turned over transcripts are stabilized by protein synthesis inhibition (38 Fig. 6 D) . Thus, c-myc expression appears to be neither necessary nor sufficient for CEM lymphocyte proliferation. Perhaps, there is some redundancy in the transcriptional activation that the MYC protein normally provides which would permit CEM cells to circumvent the cyclic AMP effect. Other members of the myc family, such as N-myc, which is known to be expressed in CEM cells (39) , could provide this function. Further study will be necessary to determine if this hypothesis is valid. Alternatively, these CEM cells may have a block distal to the purported convergence point between cyclic AMP and glucocorticoid induced apoptosis (15) since this cell line is resistant to both agents (see Table II ) although some CEM cell lines are sensitive to glucocorticoids (20) . By contrast, Deathless is sixfold resistant to dbcAMP and Forskolin but sensitive to Dexamethasone (Table HI) . However, Deathless arrests in GI phase as readily as wild-type S49 cells (Table I) . Thus, G1 cell cycle arrest is not always associated with decreased c-myc expression and, conversely, decreased c-myc expression is not always associated with G1 cell cycle arrest. While c-myc down-regulation and cyclic AMP cell cycle arrest could be mechanistically related in some cell types, it could be a protective rather than cytotoxic effect. Persistant cmyc expression is linked to apoptosis and, by contrast, cAMP Gl arrest is reversible (at least initially). It is possible that cAMP GI arrest is a physiologic mechanism to down regulate lymphocyte proliferation and the down-regulation of c-myc expression prevents cell death and permits reversal. Preliminary data from our laboratory which supports this hypothesis is that constitutive expression of c-myc may be lethal to S49 cells. Analogous experiments in a human pre-B cell line Reh have also shown that constitutive expression of c-myc did not reverse cAMP-induced cell cycle arrest (40) . Inducible expression of introduced vectors encoding the c-myc protein may help answer the question of whether cyclic AMP GI cell cycle arrest in S49 cells is mechanistically linked to c-myc gene expression.
However, comparison of c-myc expression in S49 wild type cells with the Deathless mutant (41) clearly indicate that c-myc down regulation is not an absolute requirement for GI cell cycle arrest in S49 cells. Furthermore, it suggests that c-myc downregulation may be more closely associated with apoptosis than cell cycle arrest. In summary, the relationship of c-myc expression to cell cycle progression and viability is complex and appears to vary between cell types even within the lymphoid lineages. In S49 mouse T lymphoma cells cyclic AMP downregulation of c-myc expression appears to be more closely related to a loss of viability than Gl cell cycle arrest.
